| P2093 | author name string | Rita Maalouf | |
| | Steven Bailey | |
| P2860 | cites work | Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure | Q83366366 |
| | [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure] | Q84623455 |
| | Surface plasmon resonance-based highly sensitive immunosensing for brain natriuretic peptide using nanobeads for signal amplification | Q48433475 |
| | On-chip enzyme immunoassay of a cardiac marker using a microfluidic device combined with a portable surface plasmon resonance system | Q48458854 |
| | The clearance of BNP modeled using the NT-proBNP-BNP relationship | Q48464978 |
| | Diagnostic role of plasma BNP levels in neonates with signs of congenital heart disease | Q48473989 |
| | Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction | Q48563810 |
| | Atrial Natriuretic Peptide and Brain Natriuretic Peptide Coexist in the Secretory Granules of Human Cardiac Myocytes | Q48627816 |
| | Mini sensing chip for point-of-care acute myocardial infarction diagnosis utilizing micro-electro-mechanical system and nano-technology | Q48737437 |
| | Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry | Q48792767 |
| | Cross-reactivity with endogenous proBNP from heart failure patients for three commercial BNP immunoassays | Q48858328 |
| | Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system | Q48951903 |
| | The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure | Q48971321 |
| | Quality specifications for B-type natriuretic peptide assays | Q49010260 |
| | Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT‐proBNP Guided Management of Heart Failure – SIGNAL‐HF (Swedish Intervention study – Guidelines and NT‐proBNP AnaLysis in Heart Failure) | Q51654594 |
| | Label-free electrical detection of cardiac biomarker with complementary metal-oxide semiconductor-compatible silicon nanowire sensor arrays. | Q53476198 |
| | Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain | Q68518192 |
| | Charge-induced reversible strain in a metal | Q73256807 |
| | Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations | Q73736775 |
| | Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an immunoradiometric assay method | Q73806481 |
| | Methods for reducing biosensor membrane biofouling | Q74072151 |
| | Surface-responsive materials | Q74593188 |
| | Controlled switchable surface | Q81219798 |
| | Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association | Q22241921 |
| | Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11 | Q24527775 |
| | Science review: natriuretic peptides in critical illness | Q24799740 |
| | Cardiac biomarkers: new tools for heart failure management | Q26991726 |
| | Nanoporous membranes for medical and biological applications | Q27693240 |
| | Performance characterization of an abiotic and fluorescent-based continuous glucose monitoring system in patients with type 1 diabetes | Q33441096 |
| | Interpretation and use of natriuretic peptides in non-congestive heart failure settings | Q33670478 |
| | Emerging synergy between nanotechnology and implantable biosensors: a review | Q33758263 |
| | The MiniMed Continuous Glucose Monitoring System (CGMS). | Q33811775 |
| | Molecular forms of human brain natriuretic peptide in plasma | Q34105689 |
| | Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure | Q34161199 |
| | Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide | Q34184637 |
| | State of the art of BNP and NT-proBNP immunoassays: the CardioOrmoCheck study. | Q34295200 |
| | Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women | Q34442723 |
| | The precursor to B-type natriuretic peptide is an O-linked glycoprotein | Q34533968 |
| | Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials | Q34614873 |
| | Detection of cardiac biomarkers using single polyaniline nanowire-based conductometric biosensors | Q34680828 |
| | Complications of invasive monitoring | Q34896741 |
| | B-type natriuretic peptides: a diagnostic breakthrough for clinicians. | Q35140743 |
| | BNP as discharge criteria for heart failure | Q35570395 |
| | Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes | Q35620189 |
| | Molecular physiology of natriuretic peptide signalling | Q35667249 |
| | Brain and other natriuretic peptides: molecular aspects | Q35677302 |
| | Glucose sensors: toward closed loop insulin delivery | Q35725833 |
| | Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? | Q35863535 |
| | In vivo glucose monitoring: the clinical reality and the promise | Q36059127 |
| | Can continuous glucose monitoring be used for the treatment of diabetes | Q36085807 |
| | Biosensors for real-time in vivo measurements | Q36108036 |
| | Novel markers for heart failure diagnosis and prognosis | Q36110477 |
| | Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. | Q36350919 |
| | Cardiac markers and their point-of-care testing for diagnosis of acute myocardial infarction. | Q36534336 |
| | Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results | Q36636920 |
| | Long term, implantable blood pressure monitoring systems | Q37038554 |
| | Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes | Q37105189 |
| | Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). | Q37242652 |
| | Continuous glucose monitoring in the subcutaneous tissue over a 14-day sensor wear period | Q37421643 |
| | Cardiac biomarkers and the case for point-of-care testing. | Q37422631 |
| | Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis | Q37605486 |
| | Self-management of diabetes mellitus: a critical review | Q37712198 |
| | The utility of biomarkers in sorting out the complex patient | Q37732722 |
| | The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure | Q38063118 |
| | NTproBNP: an important biomarker in cardiac diseases | Q38087411 |
| | Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure | Q38213311 |
| | B-type natriuretic peptide-guided therapy: a systematic review | Q38235223 |
| | Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study | Q38374691 |
| | BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial | Q38383948 |
| | Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome | Q39734086 |
| | Reduction in BNP levels with treatment of decompensated heart failure and future clinical events | Q39984401 |
| | Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides | Q40953337 |
| | The natriuretic-peptide family | Q41463095 |
| | Self-cleaning membrane to extend the lifetime of an implanted glucose biosensor. | Q41961733 |
| | Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality | Q42781665 |
| | Design of a self-cleaning thermoresponsive nanocomposite hydrogel membrane for implantable biosensors. | Q42829873 |
| | Natriuretic peptide receptors and the heart | Q43016831 |
| | Ultra-low fouling and functionalizable zwitterionic coatings grafted onto SiO2 via a biomimetic adhesive group for sensing and detection in complex media | Q43111818 |
| | N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study | Q43156281 |
| | New features and performance of a next-generation SEVEN-day continuous glucose monitoring system with short lag time | Q43225700 |
| | N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial | Q43549494 |
| | A reversibly switching surface | Q44281006 |
| | Use of biomarkers in the management of heart failure: are we there yet? | Q44357130 |
| | Surfaces designed for charge reversal | Q44465133 |
| | Characterization of molecular forms of probrain natriuretic peptide in human plasma | Q44516078 |
| | The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma | Q44735568 |
| | Non-covalent assembly of a photoswitchable surface | Q44744381 |
| | Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes | Q44786026 |
| | Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure | Q44801369 |
| | Toward an implantable wireless cardiac monitoring platform integrated with an FDA-approved cardiovascular stent | Q44993704 |
| | Evidence for functional heterogeneity of circulating B-type natriuretic peptide. | Q45974538 |
| | Continuous glucose monitoring and intensive treatment of type 1 diabetes | Q46380752 |
| | Electrochemical enzyme immunoassay of a peptide hormone at picomolar levels. | Q46574260 |
| | BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure | Q46757865 |
| | Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form | Q46778176 |
| | Azobenzene-containing monolayer with photoswitchable wettability. | Q46846641 |
| | Protein interactions with subcutaneously implanted biosensors | Q46858822 |
| | Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure | Q47395501 |
| | Controlled protein assembly on a switchable surface | Q47621276 |
| | Relation of ANP and BNP to their N-terminal fragments in fetal circulation: evidence for enhanced neutral endopeptidase activity and resistance of BNP to neutral endopeptidase in the fetus. | Q47712431 |
| | Simultaneous detection of C-reactive protein and other cardiac markers in human plasma using micromosaic immunoassays and self-regulating microfluidic networks | Q47874721 |
| | Highly sensitive rapid, reliable, and automatic cardiovascular disease diagnosis with nanoparticle fluorescence enhancer and mems | Q47898812 |
| | A new natriuretic peptide in porcine brain | Q48100804 |
| | Blood N-terminal proBNP as a potential indicator of cardiac preload in patients with high volume load | Q48184554 |
| | Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study | Q48194485 |
| | The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure | Q48229049 |
| | Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide | Q48235282 |
| | B-type natriuretic peptide in cardiovascular disease | Q48237778 |
| | Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy | Q48239403 |
| | Diagnostic and prognostic value of brain natriuretic peptide (BNP) concentrations in very elderly heart disease patients: specific geriatric cut-off and impacts of age, gender, renal dysfunction, and nutritional status | Q48274007 |
| | The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs | Q48274406 |
| | B-type natriuretic peptide (BNP) is more sensitive to rapid hemodynamic changes in acute heart failure than N-terminal proBNP. | Q48296165 |
| | Natriuretic peptides and cardiovascular events: more than a stretch | Q48315056 |
| | Silicon nanosensor for diagnosis of cardiovascular proteomic markers | Q48361778 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | peptide | Q172847 |
| | heart failure | Q181754 |
| | hormone | Q11364 |
| | biosensor | Q669391 |
| | nerve tissue protein | Q6996861 |
| | biomedical investigative technique | Q66648976 |
| | Natriuretic peptide, brain type | Q24721416 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 567-578 | |
| P577 | publication date | 2016-03-15 | |
| | 2016-09-01 | |
| P1433 | published in | Heart Failure Reviews | Q2167497 |
| P1476 | title | A review on B-type natriuretic peptide monitoring: assays and biosensors | |
| P478 | volume | 21 | |